Work

FibroScan-AST Score vs Liver Stiffness for the Prediction of Liver Events After HCV Cure

Year: 2025

Type: article

Abstract: Background Liver stiffness (LS) predicts liver complication occurrence in patients with hepatitis C virus (HCV) infection after sustained virological response (SVR). The FibroScan-AST (FAST) score, which includes aspartate aminotransferase (AST) and controlled attenuation parameter (CAP; measured by FibroScan), may improve the prediction ability of isolated LS. Our aim was to compare the predictive capacity of LS vs FAST in this setting. Methods Multicenter cohort study including individuals with HIV/HCV coinfection or HCV monoinfection from Spain if they had (1) LS ≥9.5 kPa pretreatment, (2) SVR with a direct-acting antiviral (DAA)–based regimen, and (3) LS and CAP measurement at SVR. Fatty liver disease (FLD) was defined as CAP ≥248 dB/m. The primary outcome was the occurrence of a liver complication (decompensation or hepatocellular carcinoma [HCC]) after SVR. Results Three hundred patients were included; 213 (71%) had HIV. At SVR, 131 (44%) had FLD. The FAST score was <0.35 in 182 (61%), 0.35–0.67 in 79 (27%), and >0.67 in 34 (12%) patients. After a median (Q1–Q3) follow-up of 73 (53–83) months, 36 (12%) liver complications (15 [5%] HCC) occurred. LS was independently associated with an increased risk of developing liver complications (sub–hazard ratio [sHR], 1.06; 95% CI, 1.04–1.08; P < .001). In a separate model, FAST ≥0.35 was also independently associated with greater risk of liver complications (sHR, 8.12; 95% CI, 3.11–21.17; P < .001). The area under the receiver operating characteristics curve of the model based on LS was 0.83 (95% CI, 0.76–0.91), and that of the model based on FAST was 0.80 (95% CI, 0.72–0.88; P = .158). Conclusions The FAST score predicts the development of liver events after SVR but does not improve the predictive capacity of LS alone at this time point.

Source: Open Forum Infectious Diseases

DOI: 10.1093/ofid/ofae628